# DSIP Peptide Benefits: What the Research Shows > DSIP peptide benefits documented across peer-reviewed human and animal studies: sleep, pain, withdrawal, narcolepsy, neuroprotection, and hormonal modulation. Research findings only. ## DSIP Peptide Benefits: What the Research Shows DSIP peptide benefits documented in peer-reviewed literature cover sleep architecture restoration, pain modulation, withdrawal management, narcolepsy, neuroprotection, and hormonal regulation. The evidence base is predominantly from the 1980s-1990s — small controlled trials, consistent internal results, but no large Phase III replication. Key findings by outcome area: - Sleep: 4 controlled human insomnia trials [1][2][3][4][5] - Pain: 6/7 chronic pain patients responded, plus depressive symptom reduction [18] - Withdrawal: 87-97% beneficial response in 107 opiate/alcohol withdrawal patients [15][16] - Narcolepsy: reduced daytime sleep attacks in a single case study [17] - Longevity/neuroprotection: 24.1% maximum lifespan extension in mouse model [25] - Hormonal: GH, LH, and pineal indolamine modulation in animal studies [6][7][19][20] ## What are the benefits of DSIP peptide? The most robustly documented benefit in humans is sleep architecture restoration in chronic insomniacs. Four controlled trials covering 43 total subjects converge on the same direction: improved sleep efficiency, shorter latency, fewer interruptions, and no daytime sedation and no rebound insomnia upon cessation [1][2][3][4]. The pain pilot study (n=7) reported significant reduction in six of seven chronic pain patients [18]. The withdrawal studies provide the largest human dataset: 107 patients, 97% opiate and 87% alcohol withdrawal response rates at 25 nmol/kg IV [16]. ## DSIP and opioid withdrawal research Dick et al. (1983) reported beneficial response in 48 of 49 evaluable patients from a combined cohort of 67 opiate and alcohol withdrawal inpatients [15]. Dick et al. (1984) extended this to 107 inpatients and found 97% response in opiate-dependent patients and 87% in alcohol-dependent patients; tolerance was generally good, with occasional headache as the only notable side effect [16]. ## Can DSIP help with narcolepsy? A single case study (Schneider-Helmert 1984, PMID 6548968) reported benefit in a 35-year-old narcoleptic male: repeated DSIP injections reduced daytime sleep attacks, increased daytime alertness and performance, enhanced nighttime REM, and compressed the nocturnal sleep period [17]. This is one patient — no controlled narcolepsy trial has been published. ## Is DSIP neuroprotective? Popovich et al. (2003) found that monthly subcutaneous Deltaran (a DSIP preparation) extended maximum lifespan in female SHR mice by 24.1%, reduced spontaneous tumor incidence 2.6-fold, and decreased bone marrow chromosome aberration frequency by 22.6% [25]. Tukhovskaya et al. (2021) found that intranasal DSIP significantly accelerated motor recovery after focal stroke in rats [28]. ## References [1] Bes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. Neuropsychobiology. 1992;26(4):193-197. https://pubmed.ncbi.nlm.nih.gov/1299794/ [2] Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP on disturbed human sleep. Experientia. 1981;37(9):913-917. https://pubmed.ncbi.nlm.nih.gov/7028502/ [15] Dick P et al. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide. Neuropsychobiology. 1983;10(4):233-237. https://pubmed.ncbi.nlm.nih.gov/6328354/ [16] Dick P et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. European Neurology. 1984;23(5):364-371. https://pubmed.ncbi.nlm.nih.gov/6548969/ [17] Schneider-Helmert D. Effects of DSIP on narcolepsy. European Neurology. 1984;23(5):353-357. https://pubmed.ncbi.nlm.nih.gov/6548968/ [18] Larbig W et al. Therapeutic effects of DSIP in patients with chronic pronounced pain episodes. European Neurology. 1984;23(5):372-385. https://pubmed.ncbi.nlm.nih.gov/6548970/ [25] Popovich IG et al. Effect of Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mechanisms of Ageing and Development. 2003;124(6):721-731. https://pubmed.ncbi.nlm.nih.gov/12782416/ [28] Tukhovskaya EA et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021;26(17):5173. https://pubmed.ncbi.nlm.nih.gov/34500605/ --- Nine residues, twenty-five studies, one grid — the DSIP peptide research record indexed by finding, not by vendor.